[/tdc_zone]
LATEST ARTICLES
Good news from uniQure: gene therapy trial on track, and promising...
The first group of 10 participants have been dosed in uniQure’s clinical trial of an HD gene therapy, and three new manuscripts describe safe,...
A NEW INTERNATIONAL CONSORTIUM TO PROMOTE STEM CELL-BASED THERAPY FOR HUNTINGTON’S...
The Stem Cells for Huntington’s Disease (SC4HD) is a new international consortium created to promote advanced therapy medicinal product (ATMP) through cell transplantation studies on...
uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease...
Publication in Science Translational Medicine shows local striatal delivery of microRNA-gene therapy results in widespread brain huntingtin protein lowering in Huntington’s disease minipigs
LEXINGTON, Mass....
UNIVERSITY
A NEW INTERNATIONAL CONSORTIUM TO PROMOTE STEM CELL-BASED THERAPY FOR HUNTINGTON’S...
The Stem Cells for Huntington’s Disease (SC4HD) is a new international consortium created to promote advanced therapy medicinal product (ATMP) through cell transplantation studies on...
New therapeutic target for Huntington’s treatment
Huntington’s disease is caused by a mutation in the Huntingtin gene (HTT), which appears in adults and features motor, cognitive and psychiatric alterations. The...
Optogenetic stimulation improves alterations in movement and behaviour of experimental models...
Huntington’s disease is an hereditary neurodegenerative disease featured by alterations in movement, cognitive deficiency and psychiatric disorders resulting from the degeneration of neurons in...
World first study reveals altered gut bacteria in Huntington’s Disease which...
The first clinical study of the gut microbiome in Huntington’s disease (HD) has found evidence of gut dysbiosis (altered bacteria in the gastrointestinal tract) in people...
HDBUZZ
Good news from uniQure: gene therapy trial on track, and promising...
The first group of 10 participants have been dosed in uniQure’s clinical trial of an HD gene therapy, and three new manuscripts describe safe,...
Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
Wave Life Sciences shared the disappointing news that their two ASOs in Phase 1/2 trials in HD patients did not successfully lower mutant huntingtin.
The...
ARTICLES
IONIS-HTTRx
